Momenta Pharmaceuticals Inc (MNTA):企業の財務・戦略的SWOT分析

◆英語タイトル:Momenta Pharmaceuticals Inc (MNTA) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C0271
◆発行会社(調査会社):GlobalData
◆発行日:2018年7月
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Momenta Pharmaceuticals Inc (MNTA) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Momenta Pharmaceuticals Inc (Momenta) is a biotechnology company which specializes in the structural analysis, characterization, and design of complex pharmaceuticals. The company’s products include Glatopa; and Enoxaparin Sodium Injection. Its pipeline portfolio encompasses candidates to substitute Copaxone 40 mg/mL, Humira, and Orencia; an anti-FcRn antibody; selective immune-modulator of Fc receptors; hyper-sialylated IVIg as well as investigational candidate for the treatment of pancreatic cancer. The company utilizes its technology for developing generic versions of biosimilars, complex drugs, and potentially interchangeable biologics, and also in the discovery and development of therapeutics for various cancers and autoimmune indications. Momenta is headquartered in Cambridge, Massachusetts, the US.

Momenta Pharmaceuticals Inc Key Recent Developments

May 08,2018: Momenta Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
Mar 21,2018: Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals and Sandoz
Feb 21,2018: Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update
Nov 01,2017: Momenta Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Oct 02,2017: Momenta Pharmaceuticals Promotes Ganesh V. Kaundinya as Chief Operating Officer and Chief Scientific Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Momenta Pharmaceuticals Inc – Key Facts 6
Momenta Pharmaceuticals Inc – Key Employees 7
Momenta Pharmaceuticals Inc – Key Employee Biographies 8
Momenta Pharmaceuticals Inc – Major Products and Services 9
Momenta Pharmaceuticals Inc – History 10
Momenta Pharmaceuticals Inc – Company Statement 12
Momenta Pharmaceuticals Inc – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Section 2 – Company Analysis 16
Company Overview 16
Momenta Pharmaceuticals Inc – Business Description 17
Momenta Pharmaceuticals Inc – SWOT Analysis 18
SWOT Analysis – Overview 18
Momenta Pharmaceuticals Inc – Strengths 18
Momenta Pharmaceuticals Inc – Weaknesses 19
Momenta Pharmaceuticals Inc – Opportunities 20
Momenta Pharmaceuticals Inc – Threats 21
Momenta Pharmaceuticals Inc – Key Competitors 22
Section 3 – Company Financial Ratios 23
Financial Ratios – Capital Market Ratios 23
Financial Ratios – Annual Ratios 24
Performance Chart 26
Financial Performance 26
Financial Ratios – Interim Ratios 27
Financial Ratios – Ratio Charts 28
Section 4 – Company’s Lifesciences Financial Deals and Alliances 29
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30
Momenta Pharmaceuticals Inc, Recent Deals Summary 31
Section 5 – Company’s Recent Developments 32
May 08, 2018: Momenta Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update 32
Mar 21, 2018: Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals and Sandoz 35
Feb 21, 2018: Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update 36
Nov 01, 2017: Momenta Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 39
Oct 02, 2017: Momenta Pharmaceuticals Promotes Ganesh V. Kaundinya as Chief Operating Officer and Chief Scientific Officer 41
Aug 02, 2017: Momenta Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update 42
Jun 01, 2017: Momenta Pharmaceuticals Appoints Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer 44
May 02, 2017: Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results 45
Feb 21, 2017: Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results 48
Jan 06, 2017: Momenta Provides Year-End 2016 Corporate Update 51
Section 6 – Appendix 53
Methodology 53
Ratio Definitions 53
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Momenta Pharmaceuticals Inc, Key Facts 6
Momenta Pharmaceuticals Inc, Key Employees 7
Momenta Pharmaceuticals Inc, Key Employee Biographies 8
Momenta Pharmaceuticals Inc, Major Products and Services 9
Momenta Pharmaceuticals Inc, History 10
Momenta Pharmaceuticals Inc, Subsidiaries 15
Momenta Pharmaceuticals Inc, Key Competitors 22
Momenta Pharmaceuticals Inc, Ratios based on current share price 23
Momenta Pharmaceuticals Inc, Annual Ratios 24
Momenta Pharmaceuticals Inc, Annual Ratios (Cont...1) 25
Momenta Pharmaceuticals Inc, Interim Ratios 27
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30
Momenta Pharmaceuticals Inc, Recent Deals Summary 31
Currency Codes 53
Capital Market Ratios 53
Equity Ratios 54
Profitability Ratios 54
Cost Ratios 55
Liquidity Ratios 55
Leverage Ratios 56
Efficiency Ratios 56

List of Figures
Momenta Pharmaceuticals Inc, Performance Chart (2013 - 2017) 26
Momenta Pharmaceuticals Inc, Ratio Charts 28
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 30

★海外企業調査レポート[Momenta Pharmaceuticals Inc (MNTA):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • General Mills Inc:戦略・SWOT・企業財務分析
    General Mills Inc - Strategy, SWOT and Corporate Finance Report Summary General Mills Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Public Financial Holdings Limited (626):企業の財務・戦略的SWOT分析
    Public Financial Holdings Limited (626) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Verizon Communications Inc (VZ):企業の財務・戦略的SWOT分析
    Verizon Communications Inc (VZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Telekom Malaysia Bhd (TM):企業の財務・戦略的SWOT分析
    Telekom Malaysia Bhd (TM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Calix Ltd (CXL):企業の財務・戦略的SWOT分析
    Calix Ltd (CXL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Aesica Pharmaceuticals Ltd:企業の戦略的SWOT分析
    Aesica Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • PetroChina Company Limited:企業の戦略・SWOT・財務分析
    PetroChina Company Limited - Strategy, SWOT and Corporate Finance Report Summary PetroChina Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Grupe SAB de CV:企業の戦略・SWOT・財務情報
    Grupe SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Grupe SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Mersana Therapeutics Inc (MRSN):製薬・医療:M&Aディール及び事業提携情報
    Summary Mersana Therapeutics Inc (Mersana) formerly Nanopharma Corp is a clinical-stage biopharmaceutical company that offers antibody drug conjugate to improve patients’ lives. The company offers pipeline product XMT-1522, for HER-2 targeted therapies based on its Dolaflexin platform. It utilizes F …
  • Sotera Health LLC:医療機器:M&Aディール及び事業提携情報
    Summary Sotera Health LLC (Sotera Health), formerly Sterigenics International LLC, a subsidiary of GTCR LLC, is a medical device company. The company offers sterilization technologies such as gamma irradiation, electron beam and ethylene oxide. Its services include drug device combination, vaccine s …
  • Robert Half International Inc (RHI):企業の財務・戦略的SWOT分析
    Robert Half International Inc (RHI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Alacer Gold Corp:企業の戦略・SWOT・財務分析
    Alacer Gold Corp - Strategy, SWOT and Corporate Finance Report Summary Alacer Gold Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Public Broadcasting Service:企業の戦略・SWOT・財務分析
    Public Broadcasting Service - Strategy, SWOT and Corporate Finance Report Summary Public Broadcasting Service - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • George Weston Limited (WN):企業の財務・戦略的SWOT分析
    George Weston Limited (WN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Neurelis Inc-製薬・医療分野:企業M&A・提携分析
    Summary Neurelis Inc. (Neurelis) is a specialty pharmaceutical company, which develops medicines to target unmet medical need in epilepsy and acute anxiety episodes. The company's product portfolio includes NRL-1 (intranasal diazepam), a proprietary formulation, for epilepsy in pediatric and adult p …
  • Bank Of Ireland (Uk) Plc:企業の戦略・SWOT・財務分析
    Bank Of Ireland (Uk) Plc - Strategy, SWOT and Corporate Finance Report Summary Bank Of Ireland (Uk) Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • AVEVA Group Plc:企業の戦略・SWOT・財務情報
    AVEVA Group Plc - Strategy, SWOT and Corporate Finance Report Summary AVEVA Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Ayala Corp (AC):企業の財務・戦略的SWOT分析
    Ayala Corp (AC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Dermalogica Inc:企業の戦略・SWOT・財務情報
    Dermalogica Inc - Strategy, SWOT and Corporate Finance Report Summary Dermalogica Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Coca-Cola FEMSA SAB de CV:企業の戦略・SWOT・財務情報
    Coca-Cola FEMSA SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Coca-Cola FEMSA SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆